U.S. markets open in 2 hours 4 minutes

Verona Pharma plc (VRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.72-0.20 (-3.38%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.92
Bid5.65 x 800
Ask6.02 x 800
Day's Range5.72 - 6.04
52 Week Range4.02 - 15.71
Avg. Volume76,539
Market Cap331.578M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study

    Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints. Dose-ordered improvement in lung function was observed and statistically significant at peak and over the 12-hour dosing interval compared with placebo, thus supporting twice-daily dosing. An increase in lung function measured by peak forced expiratory volume in one second (FEV1) were 205 mL, 277mL, and 326mL for 300 µg, 1000 µg, and 3000 µg dose, respectively. Ensifentrine pMDI formulation was well tolerated at each dose with an adverse event profile similar to placebo. The drug candidate is also under development in hospitalized COVID-19 patients, with results expected in Q2 this year. Price Action: VRNA shares are higher by 13.4% at $8.96 in the pre-market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaCan Bitcoin Be The Next GameStop? The Word On The Street102 Biggest Movers From Yesterday© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is VRNA A Good Stock To Buy Now?
    Insider Monkey

    Is VRNA A Good Stock To Buy Now?

    In this article we will check out the progression of hedge fund sentiment towards Verona Pharma plc (NASDAQ:VRNA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

  • 25 Best U.S. Cities to Live With Asthma
    Insider Monkey

    25 Best U.S. Cities to Live With Asthma

    In this article we take a look at the 25 best U.S. cities to live with asthma. Click to skip ahead and jump to the 10 best U.S. cities to live with asthma. Navigating through life with asthma can be a life-long challenge in itself. Sometimes it becomes very important to constantly monitor your surroundings […]